Allegra Hurt By Stocking, Late Allergy Season, Not Other Products – Aventis
Executive Summary
Aventis expects its allergy therapy Allegra to achieve single-digit growth in 2003 despite a slow first quarter, the company told analysts April 30
You may also be interested in...
Allegra Managed Care Talks Ongoing: Aventis Expects No “Major Shifts”
Aventis does not expect any "major shifts" in Allegra reimbursement as the company renews managed care contracts for 2004, Investor Relations Head Arvind Sood told analysts Oct. 30
Allegra Managed Care Talks Ongoing: Aventis Expects No “Major Shifts”
Aventis does not expect any "major shifts" in Allegra reimbursement as the company renews managed care contracts for 2004, Investor Relations Head Arvind Sood told analysts Oct. 30
Aventis Allegra Inventory Stable At Two Weeks; Price Flexibility “Minimal”
Aventis' inventory levels for Allegra have stabilized following first quarter wholesaler reductions triggered by the availability of OTC Claritin, VP-Investor Relations Arvind Sood told investors June 29